The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
复制标题
DOI：
10.1016/j.ygyno.2005.10.013
复制
发表时间：
2006-02-01
影响因子：
4.7
通讯作者：
Fujiwara, Y
中科院分区：
文献类型：
--
作者：
Matsumoto, K;Katsumata, N;Fujiwara, Y
Objective.伊立替康是可能有效治疗铂类和紫杉类耐药上皮性卵巢癌的药物之一。我们研究了伊立替康每周给药方案的有效性和安全性。从2001年9月至2003年3月，28名符合条件的患者谁有组织学confintied上皮性卵巢癌，这是耐药或难治铂和紫杉烷，连续治疗在国家癌症中心医院。在第1、8和15天，在90分钟内静脉给予伊立替康（100 mg/m2）。化疗每4周重复1次，共6个周期。28例患者共接受了107个伊立替康治疗周期。既往化疗方案的中位数为3。在28例患者中，8例（29%）对伊立替康有应答（2例完全应答和6例部分应答）。中位进展时间为17周。3例患者发生4级血液学毒性。5例患者发生3级或4级非血液学毒性。无治疗相关死亡。伊立替康每周给药方案似乎是铂类和紫杉类耐药或难治性上皮性卵巢癌的有效和安全的挽救化疗方案。胃肠道毒性，特别是腹泻，是中度和管理的门诊设置。(c)2005年爱思唯尔公司All rights reserved.
Objective. Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety of the weekly dosing schedule of irinotecan.Methods. From September 2001 to March 2003, 28 eligible patients who have histologically confintied epithelial ovarian cancer, which was resistant or refractory to both platinum and taxanes, were consecutively treated at the National Cancer Center Hospital. Irinotecan (100 mg/m(2)) was administered intravenously over 90 min on days 1, 8, and 15. The chemotherapy was repeated every 4 weeks, up to 6 cycles.Results. A total of 107 treatment cycles of irinotecan were administered to 28 patients. The median number of prior chemotherapy regimen was 3. Among 28 patients, 8 (29%) responded to irinotecan (2 complete responses and 6 partial responses). The median time to progression was 17 weeks. Three patients experienced hematological toxicities of Grade 4. Five patients experienced non-bematological toxicities Grade 3 or 4. No treatment-related death occurred.Conclusion. The weekly dosing schedule of irinotecan seems to be effective and safe salvage chemotherapy regimen for platinum- and taxanes-resistant or refractory epithelial ovarian cancer. Gastrointestinal toxicities, especially diarrhea, were moderate and manageable in an outpatient setting. (c) 2005 Elsevier Inc. All rights reserved.